C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 146,880 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on April 29, 2024 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州沃特敦，2024年4月29日（GLOBE NEWSWIRE）——致力於推進靶向蛋白降解科學的臨床階段生物製藥公司C4 Therapeutics, Inc.（C4T）（納斯達克股票代碼：CCCC）今天宣佈，在公司董事會組織、領導和薪酬委員會任職的獨立董事批准授予購買146,880股股票的非合格股票期權公司向一名新員工發放普通股（“激勵補助金”），補助金於2024年4月29日（“授予日期”）發放。根據納斯達克上市規則5635（c）（4），激勵補助金是作爲物質誘因發放的，是激勵該個人在C4T工作。
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T's common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee's start date, with the remainder of the shares vesting in twelve equal quarterly installments thereafter, subject to the employee's continued employment with C4T through each vesting date.
激勵補助金的每股行使價等於C4T普通股在授予日的收盤價。激勵補助金將在四年內歸屬，其中 25% 的股份將在員工入職一週年之際歸屬，其餘股份將分十二個等額的季度分期歸屬，前提是員工在每個歸屬日之前繼續在C4T工作。
About C4 Therapeutics
關於 C4 療法
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
C4 Therapeutics（C4T）（納斯達克股票代碼：CCCC）是一家臨床階段的生物製藥公司，致力於兌現靶向蛋白質降解科學的承諾，創造改變患者生活的新一代藥物。C4T正在通過臨床研究和利用其TORPEDO推進靶向腫瘤學項目 該平台可高效設計和優化小分子藥物，以解決難以治療的疾病。C4T的降解劑藥物旨在利用人體的天然蛋白質回收系統快速降解致病蛋白，從而有可能克服耐藥性、不可藥物靶標和改善患者預後。欲了解更多信息，請訪問 www.c4therapeutics。
Contacts:
聯繫人：
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
投資者：
考特尼·索爾伯格
投資者關係高級經理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒體：
洛蘭·斯普林
企業傳播與患者宣傳高級董事
LSpreen@c4therapeutics.com
